Abstract:Summary of the study design and key findings. In the central panel, (+) and (−) means that the variable is directly or inversely associated with beta‐hydroxybutyrate (β‐OHB) levels, respectively. The gold arrow means that free fatty acid (FFA) levels are the only variable that remained associated with β‐OHB levels in the multivariable model. HFrEF, heart failure with reduced ejection fraction; HOMA‐IR, homeostasis model assessment of insulin resistance; LV, left ventricular; RHC, right heart catheterization; RV, right ventricular; TG, triglycerides. Parts of the figure were created using Biorender.com. Aims Patients with heart failure (HF) display metabolic alterations, including heightened ketogenesis, resulting in increased beta‐hydroxybutyrate (β‐OHB) formation. We aimed to investigate the determinants and prognostic impact of circulating β‐OHB levels in patients with advanced HF and reduced ejection fraction (HFrEF). Methods and results A total of 867 patients with advanced HFrEF (age 57 ± 11 years, 83% male, 45% diabetic, 60% New York Heart Association class III), underwent clinical and echocardiographic examination, circulating metabolite assessment, and right heart catheterization (n = 383). The median β‐OHB level was 64 (interquartile range [IQR] 33–161) μmol/L (normal 0–74 μmol/L). β‐OHB levels correlated with increased markers of lipolysis (free fatty acids [FFA]), higher natriuretic peptides, worse pulmonary haemodynamics, and lower humoral regulators of ketogenesis (insulin/glucagon ratio). During a median follow‐up of 1126 (IQR 410–1781) days, there were 512 composite events, including 324 deaths, 81 left ventricular assist device implantations and 107 urgent cardiac transplantations. In univariable Cox regression, increased β‐OHB levels (T3 vs. T1: hazard ratio [HR] 1.39, 95% confidence interval [CI] 1.13–1.72, p = 0.002) and elevated FFA levels (T3 vs. T1: HR 1.39, 95% CI 1.09–1.79, p = 0.008) were both predictors of a worse prognosis. In multivariable Cox analysis evaluating the simultaneous associations of FFA and β‐OHB levels with outcomes, only FFA levels remained significantly associated with adverse outcomes. Conclusions In patients with advanced HFrEF, increased plasma β‐OHB correlate with FFA levels, worse right ventricular function, greater neurohormonal activation and other markers of HF severity. The association between plasma β‐OHB and adverse outcomes is eliminated after accounting for FFA levels, suggesting that increased β‐OHB is a consequence reflecting heightened lipolytic state, rather than a cause of worsening HF.

A Retrospective Study on the Relationship Between Plasma Β-Hydroxybutyric Acid Levels and Short-Term Prognosis of Cardiac Function in Patients with Acute Myocardial Infarction Combined with Heart Failure

Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy.

The relationship of α-hydroxybutyrate dehydrogenase with 1-year outcomes in patients with intracerebral hemorrhage: A retrospective study

Effects of Hemoglobin Levels on Long-Term Prognosis in Patients with Acute ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Serum Free Fatty Acids Independently Predict Adverse Outcomes in Acute Heart Failure Patients

Β-Hydroxybutyrate Exacerbates Hypoxic Injury by Inhibiting HIF-1α-Dependent Glycolysis in Cardiomyocytes—Adding Fuel to the Fire?

Circulating ketone bodies and mortality in heart failure: a community cohort study

The use of high-sensitivity cardiac troponin T and creatinine kinase-MB as a prognostic markers in patients with acute myocardial infarction and chronic kidney disease

Effect Of Urinary Kidney Injury Molecule-1 Levels On Short-Term Prognosis Of Chronic Heart Failure

The relationship between cardiac oxidative stress, inflammatory cytokine response, cardiac pump function, and prognosis post-myocardial infarction

Prognostic value of gut microbiota-derived metabolites in patients with ST-segment elevation myocardial infarction

Elevated α-hydroxybutyrate dehydrogenase is associated with in-hospital mortality in non-ischemic dilated cardiomyopathy

The impact of circulating IGF-1 and IGFBP-2 on cardiovascular prognosis in patients with acute coronary syndrome

Health Status Predicts Short- and Long-Term Risk of Composite Clinical Outcomes in Acute Heart Failure.

Circulating beta‐hydroxybutyrate levels in advanced heart failure with reduced ejection fraction: Determinants and prognostic impact

Therapeutic and Prognostic Significance of Arachidonic Acid in Heart Failure

The effect of zomepirac on red blood cell survival and immune system.

Clinico-pathological features of colorectal adenomatous polyps with negative results on immunochemical fecal occult blood test.

Circulating 3‐hydroxy butyrate predicts mortality in patients with chronic heart failure with reduced ejection fraction

Clinical study on relationship of hs-CRP level with presence and prognosis of cardiac dys-function in patients with type 2 diabetes after percutaneous coronary intervention

Ketone Body β-Hydroxybutyrate Prevents Myocardial Oxidative Stress in Septic Cardiomyopathy